LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

Strona główna・Stock List・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Closed

SectorHealthcare

596.82 -0.18

Buy Sell

Overview

Share price change

24h

Current

Min

589.29

Max

600.56

Key metrics
By Trading Economics
Income	-72M -114M
Sales	74M 287M
EPS	-4.956
Profit margin	-39.75
Employees	528
EBITDA	-75M -114M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	-6.54% downside

Market Stats
By TradingEconomics
Market Cap	4.2B 13B
Previous open	597
Previous close	596.82

News Sentiment

By Acuity

64%

36%

334 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

263.2 / 277.1 Support & Resistance

Madrigal Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

28 lis 2025, 15:29 UTC

Major Market Movers

Acquisitions, Mergers, Takeovers

China's Jiangxi Copper Rejected by SolGold in $1 Billion Takeover Approach

28 lis 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

28 lis 2025, 19:59 UTC

Market Talk

Oil Futures Settle Lower in Slow Black Friday Trade -- Market Talk

28 lis 2025, 19:47 UTC

Market Talk

U.S. Natural Gas Lifted By Cold Weather Outlook -- Market Talk

28 lis 2025, 18:16 UTC

Market Talk

Global Equities Roundup: Market Talk

28 lis 2025, 18:16 UTC

Market Talk

Messy Canada GDP Data Still Seen as Cause for Optimism in 2026 -- Market Talk

28 lis 2025, 18:08 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

28 lis 2025, 18:08 UTC

Market Talk

Messy Canada GDP Data Still Seen as Cause for Optimism in 2026 -- Market Talk

28 lis 2025, 17:48 UTC

Market Talk

Bank of Canada May Revise Up Inflation Projections After GDP Data -- Market Talk

28 lis 2025, 17:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

28 lis 2025, 16:50 UTC

Acquisitions, Mergers, Takeovers

Week's Best: Sieg's Stature at Citi Grows -- Barrons.com

28 lis 2025, 15:51 UTC

Market Talk

Canada Household Spending Edges Lower -- Market Talk

28 lis 2025, 15:33 UTC

Market Talk

Crude Futures Gain as U.S. Market Reopens -- Market Talk

28 lis 2025, 15:21 UTC

Market Talk

Gold Rises on U.S. Rate-Cut Bets After CME Outage -- Market Talk

28 lis 2025, 15:13 UTC

Market Talk

Dollar Recovers Slightly as Investors Already Price in Fed Rate Cut -- Market Talk

28 lis 2025, 15:11 UTC

Market Talk

Global Equities Roundup: Market Talk

28 lis 2025, 15:11 UTC

Market Talk

Canadian National Railway Showing Positive Trend Going Into 2026 -- Market Talk

28 lis 2025, 14:51 UTC

Market Talk

Canada GDP Report Masks Fragile State of Economy -- Market Talk

28 lis 2025, 14:41 UTC

Market Talk

Canada's GDP Level Pulled Higher by 'Eye-Opening' Revisions -- Market Talk

28 lis 2025, 14:37 UTC

Market Talk

U.S. Natural Gas Futures Rise As Temperatures Drop -- Market Talk

28 lis 2025, 14:33 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28 lis 2025, 14:33 UTC

Market Talk

Steep Import Drop Fuels Surprise Lift in Canada GDP -- Market Talk

28 lis 2025, 14:20 UTC

Market Talk

Too Much Noise in Canada's Surprise 3Q GDP Gain -- Market Talk

28 lis 2025, 14:10 UTC

Market Talk

Canadian Nowcast Came Closest to Predicting Surprise 3Q Strength -- Market Talk

28 lis 2025, 13:39 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28 lis 2025, 13:39 UTC

Market Talk

Canada Trade Data Could Face Larger-Than-Normal Revisions -- Market Talk

28 lis 2025, 13:36 UTC

Market Talk

Canada's Economy Expands More Than Expected -- Market Talk

28 lis 2025, 13:29 UTC

Market Talk

CME Outage Sowing Chaos Across Markets, Trade Nations Says -- Market Talk

28 lis 2025, 13:27 UTC

Market Talk

Russia-Ukraine Peace Efforts to Have Little Impact on Oil Fundamentals -- Market Talk

28 lis 2025, 13:19 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Peer Comparison

Price change

Madrigal Pharmaceuticals Inc Forecast

Price Target

By TipRanks

-6.54% downside

12 Months Forecast

Average 561.73 USD -6.54%

High 650 USD

Low 445 USD

Based on 12 Wall Street analysts offering 12 month price targets forMadrigal Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Based on 12 analysts giving stock ratings to Madrigal Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

263.2 / 277.1Support & Resistance

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

334 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.